The combination of Bosutinib with the PI3Kα inhibitor Alpelisib, which has shown good efficacy and tolerability in several cancers, including HNSCC [17,18,19], efficiently inhibited both EGFR/ERK and PI3K pathways in HNSCC cell lines. Here, PIK3CA is linked to cancer.